Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rilvegostomig
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Rilvegostomig is a bispecific monoclonal antibody designed to target and inhibit both programmed cell death protein 1 (PD-1) and T cell immunoreceptor with Ig and ITIM domains (TIGIT). By simultaneously blocking these two immune checkpoint pathways, rilvegostomig aims to enhance T-cell mediated anti-tumor responses. It is being developed primarily as an immunotherapy for various cancers. Rilvegostomig is currently in Phase III clinical trials for several indications including non-small cell lung cancer, biliary tract cancer, endometrial cancer, liver cancer, and adenocarcinoma. The drug is administered intravenously[2][3][4][5][6].
- Brand names
- rilvegostomig
- Other names
- rilvegostomig
02
Targets
TIGIT (T cell immunoreceptor with Ig and ITIM domains)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on rilvegostomig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rilvegostomig.